METHOD FOR DETECTING RISK GROUPS IN DEVELOPING NERVOUS-PSYCHIC DISEASES Russian patent published in 2003 - IPC

FIELD: medicine. SUBSTANCE: one should carry out immuno-enzymatic assay by using ELI-N-1 test system that is either antigens of nervous tissue (AGNt) sorbed onto plotting boards or their immunochemical analogs specifically binding autoantibodies with tendency towards AGNt, and, also, idiotypical antibodies (AB1) or their variable sections specifically binding corresponding AGNt. Moreover, in dynamics one should detect serumal AB1 level, the level of corresponding antiidiotypical antibodies (AB2) and coefficient (C) 1 being the ratio of AB2/AB1. If reactive intensity of tested serum (RITS) with any component of test system does not come beyond within 65-135% against reaction of standard serum (RSS), and all detectable C 1 are within 0.7-1.3 it is possible to refer this serum to group 1 - minimal risk degree; if RITS is beyond group 1 but corresponds to not less than 40% and not more than 180% against RSS, or any C 1 is beyond 0.7-1.3 but corresponds not less than 0.5 and not more than 1.5 one should refer this serum to group 2 - weak risk degree; if RITS is beyond groups 1 and 2 or C 1 is beyond 0.5-1.5 the present serum is referred to group 3 - high risk degree in development of nervous-psychic diseases. EFFECT: higher efficiency. 4 ex, 10 tbl